Company intelligence / Profile preview
Eikon Therapeutics
Hayward, California, United Stateseikontx.com ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Phase 3
01
Overview
Lead program EIK1001 (TLR7/8 co-agonist) is in Phase 3 for advanced melanoma, showing single-agent efficacy and promising combination activity with anti-PD-(L)1 agents. EIK1003 (selective PARP1 inhibitor) is in Phase 1 for breast, ovarian, prostate, and pancreatic cancers. EIK1004 (CNS-penetrant PARP1 inhibitor) is poised to begin Phase 1 studies for brain cancers[3][6].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Eikon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eikon Therapeutics.